What Are Analysts Saying About Pfizer?

What Are Analysts Saying About Pfizer?

After a lackluster start to 2016, Pfizer’s (PFE) stock price is currently trending upwards, albeit at a slow pace. The performance of Pfizer according to a historical stock chart indicates a clear downward trend from May 2015 all the way through to February 2016. However, a reversal appears to be taking place with bullish momentum […]
RBA Holds Rates Steady At 2.0%

RBA Holds Rates Steady At 2.0%

The RBA’s monetary policy meeting today saw the key rates left unchanged at 2.0%. The RBA cut interest rates in May 2015 and has left rates unchanged since then. However, the focus of today’s monetary policy meeting was the recent appreciation in the exchange rate of the Australian dollar leading many to speculate on the […]
Biotech: Time To Buy Or Sell? Surprising Stock Tips

Biotech: Time To Buy Or Sell? Surprising Stock Tips

Biotechnology is one of those sectors that is totally out of grace after it came down sharply in the second half of 2015, as market volatility rose sharply. The first chart shows that the biotech index (represented by the IBB ETF) lost 40% of its value in just 7 months. Talking about a sharp correction! That could […]
Aeglea Biotherapeutics IPO: Wait For Larger April Deals

Aeglea Biotherapeutics IPO: Wait For Larger April Deals

Aeglea Biotherapeutics Inc. (AGLE) expects to raise $51.4 million in its upcoming IPO. Based in Austin, Texas, Aeglea Biotherapeutics is a biotechnology company developing enzyme-based therapeutics to treat disorders of metabolism and cancer. AGLE will offer 3.5 million shares at an expected price range of $16 to $18. CRVS filed for the IPO on June 16, 2015. […]
Triffin’s Paradox Revisited: Crunch-Time For The U.S. Dollar And The Global Economy

Triffin’s Paradox Revisited: Crunch-Time For The U.S. Dollar And The Global Economy

While all eyes on fixated on global stock markets as the measure of “prosperity” and “growth” (or is it hubris?), the larger force at work beneath the dovish cooing of central bankers is foreign exchange: the relative value of nations’ currencies, which are influenced (like everything else) by supply and demand, which is in turn influenced […]
USDJPY: Pressure Builds Up On Key Support Zone

USDJPY: Pressure Builds Up On Key Support Zone

USDJPY: The pair extended its weakness on Monday leaving lower towards its key support located at the 111.66 level. On the downside, support comes in at the 111.00 level where a break if seen will aim at the 110.50 level. A cut through here will turn focus to the 110.00 level and possibly lower towards […]
Binary Options Assets In Focus – April 5, 2016

Binary Options Assets In Focus – April 5, 2016

The session on Tuesday features of the ISM Non-manufacturing PMI numbers coming out of America, and the Australian central bank releasing its monetary policy statement an interest-rate decision. With this being said, it is not likely to be a major shift in momentum as far as the markets are concerned during the day, but those […]
Groupon Announces $250M Atairos Investment, Potential Partnership With Comcast

Groupon Announces $250M Atairos Investment, Potential Partnership With Comcast

Shares of Groupon (GRPN) rallied in morning trading after the company announced a $250M investment from Atairos, the company founded by former Comcast (CMCSA, CMCSK) vice chairman and chief financial officer Michael Angelakis. As a result of the investment, Groupon said that Comcast will work with it to identify and implement possible partnership opportunities and […]
Healthcare Stocks Lead On A Lackluster Day

Healthcare Stocks Lead On A Lackluster Day

Healthcare Sector Leads the Market  Lagging healthcare and biotech stocks found buyers today. The healthcare SPDR ETF (XLV) was up 1.05% to $69.38 as investors were probably seeking dividends and safety with fears about pricing tempered. The XLV is still down 3.68% YTD. Biotechs came out of the box strong but sold off as the […]
The Fed: Their Dangerous Obsession

The Fed: Their Dangerous Obsession

Albert discusses his recent interview with James Rickards and takes apart an Financial Times article critical of gold investors. Video Length: 00:18:25